A Phase 1, Single Dose Pk And Safety Study With Ni-03 Followed By A Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study To Evaluate The Safety And Efficacy Of Ni-03 Compared To Placebo In Subjects With Chronic Pancreatitis
Principal Investigator (?)
The purpose of this study is to determine the safety and efficacy of NI-03.
KC Specialty Therapeutics, LLC.
Available at the following location(s)